IP Library Granted Patent US 7,820,807
Granted Patent B2
US 7,820,807 · App. 12/420,481 · Granted Oct 26, 2010

Gene constructs coding for CD40-binding activating antibodies

Assignee: Pangenetics BV
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,807
App. No.
12/420,481
Granted
Oct 26, 2010
Kind
B2
Abstract

Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.

Claims (6)

1. A gene construct coding for an anti-CD40 monoclonal antibody, wherein said anti-CD40 antibody is produced by a hybridoma selected from the group consisting of hybridomas deposited with American Type Culture Collection (ATCC) as deposit designation PTA-2993, PTA-2994, PTA-2995, PTA-2996, PTA-2997, PTA-2998 and PTA-2999.

2. A gene construct coding for a fragment, of an anti-CD40 antibody produced by a hybridoma selected from the group consisting of hybridomas deposited with American Type Culture Collection (ATCC) as deposit designation PTA-2993, PTA-2994, PTA-2995, PTA-2996, PTA-2997, PTA-2998 and PTA-2999.

3. A cell transfected with a gene construct according to claim 1 .

4. A cell transfected with a gene construct according to claim 2 .

5. The gene construct of claim 1 or 2 , wherein the anti-CD40 antibody is a chimeric, humanized, Deimmunised™, or human antibody.

6. A cell transfected with the gene construct of claim 5 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: CLUSTER40 THERAPEUTICS B.V.
To: MYCENAX BIOTECH INC.
Reel/Frame 043119/0407 →
CHANGE OF NAME Recorded Aug 18, 2016
From: BIOCEROS HOLDING B.V.
To: CLUSTER40 THERAPEUTICS B.V.
Reel/Frame 039735/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2015
From: PANGENETICS B.V.
To: BIOCEROS HOLDING B.V.
Reel/Frame 035106/0428 →
Continuity (4)
Division 1161340900 · Dec 20, 2006
Division 0977386600 · Feb 1, 2001
Provisional Application 6017893400 · Feb 1, 2000
Related Publication 20090311268A1 · Dec 17, 2009